Skip to main content

Satsuma Pharmaceuticals, Inc. (STSA)

NASDAQ: STSA · IEX Real-Time Price · USD
5.80
+0.19 (3.39%)
After-hours:Oct 22, 2021 4:54 PM EDT
5.61
0.08 (1.45%)
At close: Oct 22, 4:00 PM
Market Cap176.88M
Revenue (ttm)n/a
Net Income (ttm)-46.81M
Shares Out31.53M
EPS (ttm)-2.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume139,082
Open5.61
Previous Close5.53
Day's Range5.42 - 5.75
52-Week Range3.50 - 7.48
Beta1.19
AnalystsBuy
Price Target11.67 (+108.0%)
Est. Earnings DateNov 9, 2021

About STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

IndustryPharmaceuticals
IPO DateSep 13, 2019
CEOJohn Kollins
Employees22
Stock ExchangeNASDAQ
Ticker SymbolSTSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for STSA stock is "Buy." The 12-month stock price forecast is 11.67, which is an increase of 108.02% from the latest price.

Price Target
$11.67
(108.02% upside)
Analyst Consensus: Buy

News

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

1 week ago - GlobeNewsWire

Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal ...

3 weeks ago - GlobeNewsWire

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal ...

1 month ago - GlobeNewsWire

Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights

- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-

2 months ago - GlobeNewsWire

Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acu...

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

2 months ago - GlobeNewsWire

Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum

SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

4 months ago - GlobeNewsWire

Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS...

- All three dose strengths of STS101, administered with improved 2 nd -generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile -

4 months ago - GlobeNewsWire

Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-

5 months ago - GlobeNewsWire

Why Earnings Season Could Be Great for Satsuma Pharmaceuticals (STSA)

Satsuma Pharmaceuticals (STSA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022

6 months ago - GlobeNewsWire

Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) will conduct a new Phase 3 efficacy trial for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine. The study will start in ...

7 months ago - Benzinga

Satsuma Pharmaceuticals Announces Updated STS101 Development Plan

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-

7 months ago - GlobeNewsWire

Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference 

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate i...

10 months ago - GlobeNewsWire

Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroergotamine ...

11 months ago - GlobeNewsWire

Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences

- Credit Suisse - 29th Annual Healthcare Conference - November 9 th -1 2 th

11 months ago - GlobeNewsWire

Satsuma Pharmaceuticals Enters Oversold Territory

Satsuma Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Satsuma Plunges on Disappointing Data on Migraine Treatment

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

1 year ago - Zacks Investment Research

Why Satsuma Pharmaceuticals Stock Is Plummeting Today

Investors are reeling from a late-stage flop for the company's only pipeline candidate.

1 year ago - The Motley Fool

This Late-Stage Study Is Giving Satsuma Pharma Stock Migraines

Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) has reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.

1 year ago - 24/7 Wall Street

Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, President a...

1 year ago - GlobeNewsWire

Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today summarized recent business progress  and ...

1 year ago - GlobeNewsWire

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101

ASCEND results expected to support STS101 NDA filing in Q4 2021

1 year ago - GlobeNewsWire

Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharma...

1 year ago - GlobeNewsWire

Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted vi...

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

1 year ago - GlobeNewsWire

Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine

More than 1,140 patients randomized and topline results expected in second half 2020 More than 1,140 patients randomized and topline results expected in second half 2020

1 year ago - GlobeNewsWire